Bruker AXS has promoted Bernard Kolodziej as vice president of finance. Kolodziej was originally hired by Bruker AXS in 1997 and has been CFO for the European operations of Bruker AXS since January 1999. Before joining the company, he held several operations and financial positions with the Siemens' X-ray business. He has a master's degree in business administration, finance, and production engineering from the
Prometheus Laboratories has appointed Bruce Neri as vice president of diagnostics R&D, and
Neri joins Prometheus from Third Wave Technologies, where he was most recently senior vice president of R&D for its Invader technology. Prior to joining Third Wave, he was vice president of DNA probe development at Becton Dickinson. Shores served in various executive roles at companies such as Amgen and Abbott.
Interleukin Genetics has appointed Taha Keilani as medical director; Christopher Palatucci as senior director of business development and licensing; Paul Voegelin as director of operations and planning; and Gary Breton as DNA laboratory manager.
Keilani comes to Interleukin from Serono, where he was medical director of clinical development and regulatory affairs. Palatucci comes to Interleukin from Athena Diagnostics, where he was director of business development. Voegelin comes to Interleukin from Genuity Solutions, where he was director of operations. Breton comes to the company from Genome Therapeutics, where he was project manager and senior scientist.
AVI BioPharma has appointed Peter O'Hanley as senior vice president of clinical development and regulatory affairs, and Ray Cummings as vice president of business development.
O'Hanley comes to the company from Maxygen, where he was vice president of clinical development. He received his PhD and MD degrees from the Medical University of South Carolina, and obtained his MPH at the
Cummings comes to AVI from Cummings Consulting, where he was founder and president. Before founding the firm, he was a vice president of business development at Aradigm. Cummings received his MBA from the
Orion Genomics has promoted Jeffrey Jeddeloh to be director of biomarker discovery and detection. Jeddeloh's primary responsibility will be to discover and develop assays for detecting epigenetic biomarkers linked to certain cancers.
Jeddeloh joined Orion from the United States Army where he served as a principal investigator at the US Army Medical Research Institute of Infectious Diseases. He received his PhD in molecular genetics from
CombiMatrix has named Mark Kay to its scientific advisory board. Kay is professor in the departments of pediatrics and genetics, and the director of the program in human gene therapy at the Stanford University School of Medicine.